Abstract
Chronic obstructive pulmonary disease (COPD) has a varying frequency and severity of exacer-bations. The fixed combination of tiotropium / olodaterol (TIO/OLO) demonstrate a reduction of risk moderate and severe exacerbations compare to tiotropium (TIO) in patients with COPD. Ti-otropium-olodaterol reduced the rate of exacerbations treated with systemic corticosteroids (SCS) alone, and reduced the rate of exacerbations treated with SCS and antibiotics compared with tiotropium.. There was no difference in the number of adverse events including major ad - verse cardiac events between TIO/OLO and tiotropium groups.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
